Dr. Reddy's Approves FY26 Results, Recommends Dividend, and Strengthens Board Leadership

Dr. Reddy's Approves FY26 Results, Recommends Dividend, and Strengthens Board Leadership​

Dr. Reddy's Laboratories Limited announced the outcome of its Board of Directors meeting held on May 12, 2026. The Board approved the audited financial results for the quarter and full financial year ended March 31, 2026, alongside several key corporate governance approvals, including the re-appointment of directors and the appointment of statutory auditors.

The Board also recommended a final dividend of INR 8/- per equity share, subject to approval from the shareholders at the ensuing Annual General Meeting.

Financial Performance Overview (FY26 Results)​

The company announced its audited consolidated financial results for the quarter and year ended March 31, 2026.

The following table summarizes the key financial figures reported in the audited consolidated financial results (amounts in Indian Rupees millions):


Segment Revenue Highlights
The consolidated segment revenue and results show the following performance:

Corporate Governance and Appointments​

The Board of Directors approved several key appointments and changes to the company's corporate structure:

Board Directorships:

• Re-appointment of Independent Director: Dr. K P Krishnan was approved for a second term of five consecutive years, running from January 7, 2027, to January 6, 2032, not liable to retire by rotation.
• New Independent Director: Mr. Srikanth Velamakanni was approved for appointment as an Additional Director, categorized as an Independent Director, for a term of five consecutive years, from July 1, 2026, to June 30, 2031.

Auditors and Management:

• Statutory Auditors: M/s Deloitte Haskins & Sells, LLP, Chartered Accountants, were approved for appointment as the Statutory Auditors for a term of five consecutive years, beginning from the conclusion of the 42nd Annual General Meeting till the 47th AGM.
• Cost Auditors: M/s Sagar & Associates, Cost Accountants, were re-appointed as the Cost Auditors for the Financial Year 2026-27.
• Senior Management: Mr. Sandeep Khandelwal, Global Generics India Head, was elevated as a Senior Management Personnel of the Company and inducted as a member of the Management Council, effective May 12, 2026.

Key Operational Announcements​

The Board also approved the convening of the 42nd Annual General Meeting (AGM) on Thursday, July 23, 2026.

In addition to the operational updates, the company announced the following financial impacts for the period ended March 31, 2026, including:

• Dividend Recommendation: A final dividend of INR 8/- per equity share of face value of Rs. 1/- each was recommended, subject to the approval of the shareholders.
• Tax Audit: The company confirmed receiving a letter from the Federal Tax Service authorities stating that the originally proposed VAT liability was substantially reduced, resulting in an additional provision of Rs. 1,141 million recognized under Other Expenses for the quarter ended March 31, 2026.

Financial Tables: Consolidated Statements of Financial Position (All amounts in Indian Rupees millions)


Note: Total liabilities calculation based on the provided data in the consolidated balance sheet.

Financial Tables: Consolidated Statements of Cash Flows (All amounts in Indian Rupees millions)

DRREDDY Stock Price Movement​

Today, Dr. Reddy's Laboratories Limited shares slipped by 0.97% to settle at ₹1270. The stock recorded robust trading volume of 1.95 million shares, closing near its intra-day low of ₹1264.5.